


Safety and Efficacy of Treatment With Once-Daily Ledipasvir/Sofosbuvir (90/400 mg) for 12 Weeks in Genotype 1 HCV-Infected Patients With Severe Renal Impairment Eric Lawitz,¹ Charles S. Landis,² Benedict J. Maliakkal,³ Maurizio Bonacini,⁴ Grisell Ortiz-Lasanta,⁵ Jie Zhang,⁶ Erik Mogalian,⁶

Introduction **Sofosbuvir and Ledipasvir** LDV NS5A inhibitor Sofosbuvir Ledipasvir - Once-daily, oral, 90-mg NS5A inhibitor SOF LDV Nucleotide NS5A polymerase inhibitor inhibitor LDV/SOF FDC - Once-daily, oral, FDC (90/400 mg) tablet Single-tablet regimen for HCV FDC, fixed-dose combination; HCV, hepatitis C virus

Despite higher concentrations of the primary circulating SOF metabolite GS-331007 in patients with severe renal impairment (RI), retrospective case series and claims database analyses have suggested substantial use of LDV/SOF in this population with no untoward effects¹⁻⁷


Objectives

To evaluate the safety and efficacy of LDV/SOF for 12 weeks in patients with chronic HCV genotype (GT) 1 or 4 infection and severe RI not undergoing dialysis



- In this Phase 2, open-label study (NCT01958281), patients in Cohort 3 were treated for 12 weeks with LDV/SOF (90/400 mg) daily
- Enrolled at 8 sites in New Zealand and USA
- ♦ Key eligibility criteria: severe RI (creatinine clearance [CLcr] ≤30 mL/min [Cockcroft-Gault equation]), HCV GT 1 or 4, and not undergoing dialysis
- Regimens:
- Cohort 1: SOF 200 mg and RBV 200 mg qd
- Cohort 2: SOF 400 mg and RBV 200 mg qd
- Cohort 3: LDV/SOF 90/400 mg
- Primary efficacy endpoint: SVR12 – HCV RNA < lower limit of quantitation (<15 IU/mL) at posttreatment Week 12 (analyzed by COBAS[®] AmpliPrep/COBAS[®] TaqMan[®] HCV Quantitative Test,
- v2.0 [Roche Molecular Diagnostics, Pleasanton, CA])
- Safety: adverse events (AEs), discontinuations (D/C) due to AEs, laboratory abnormalities, electrocardiograms, and echocardiograms
- Pharmacokinetics (PK): SOF, GS-331007, and LDV area under the curve over the dosing interval (AUC $_{\tau}$)


Shampa De-Oertel,⁶ Anu O. Osinusi,⁶ Diana M. Brainard,⁶ John G. McHutchison,⁶ Steven L. Flamm,⁷ Stuart C. Gordon,⁸ Edward J. Gane⁹ ¹UT Health San Antonio, Texas Liver Institute, San Antonio, TX; ²UW Medical Center, Seattle, WA; ³The University of Tennessee, Memphis; ⁴Mission Gastroenterology & Hepatology, University of California, San Francisco; ⁵Fundación de Investigación, San Juan, PR; ⁶Gilead Sciences, Inc., Foster City, CA; ⁷Northwestern University, Chicago, IL; ⁸Henry Ford Health System, Detroit, MI; ⁹Auckland Clinical Studies Ltd, Auckland, New Zealand




Results


Demographics	LDV/SOF, 12 Weeks n=18
Mean age, y (range)	57 (32–66)
Male, n (%)	12 (67)
White, n (%)	8 (44)
Black, n (%)	10 (56)
Mean BMI, kg/m ² (range)	30 (21–39)
Mean eGFR, mL/min/1.73 m ² (range)	24.9 (9.0–39.6)
Cirrhosis, n (%)	2 (11)
HCV GT 1 (total), n (%)	18 (100)
1a	14 (78)
1b	4 (22)
IL28B non-CC, n (%)	17 (94)
Mean HCV RNA, log10 IU/mL (range)	6.2 (5.0–7.1)


All 18 patients completed treatment





Pharmacokinetics







 Mean SOF exposure was 103% higher in patients with severe RI (n=17) than in the LDV/SOF Phase 2/3 population (N=1118) The observed change is less than that observed in a Phase 1 study evaluating the impact of RI on SOF PK, where mean SOF exposure in subjects with severe RI was 170% higher vs those with normal renal function^{8,9}

 Mean GS-331007 exposure was 501% higher in patients with severe RI (n=17) than in the LDV/SOF Phase 2/3 population (N=1602)

 This result is consistent with the PK difference observed following administration of a single dose of SOF to subjects with severe RI or normal renal function in a Phase 1 study^{8,9}





Cardiac Safety

Conclusions

- Treatment with the single-tablet regimen of LDV/SOF for 12 weeks resulted in a 100% SVR12 rate in patients with severe RI
- Treatment was safe and well tolerated

Death

Grades 3-4

– AEs were consistent with those anticipated for this patient population Plasma concentrations of the terminal SOF metabolite GS-3310007 were ~6-fold higher than in the LDV/SOF Phase 3 trials LDV and SOF plasma concentrations were similar to those observed in patients with normal, mild, or moderate RI

References

1. Beinhardt S, et al. Transpl Int 2016;29:999-1007; 2. Bhamidimarri KR, et al. J Hepatol 2015;63:763-5; 3. Dumortier J, et al. Nephrol Dial Transplant 2016 Oct 19 [Epub]; 4. Hundemer GL, et al. Infect Dis 2015;47:924-9; 5. Nazario HE, et al. J Hepato 2017;66:S507; 6. Saxena V, et al. Liver Int 2016;36:807-16; 7. Singer AW, et al AASLD 2016, poster 804; 8. Comprobet MT, et al. J Hepatol 2012;56:S389-S548, poster 1101; 9. Mogalian E, et al. J Hepatol 2014;60(suppl):1145A-6A (abstr 1952).

Acknowledgments

Disclosures



Gilead Sciences, Inc 333 Lakeside Drive Foster City, CA 94404 800-445-3235

Dh	armacokinetic	C		
F II	amacokinetic	5		
100,000 \neg LDV AUC _T				
			 Mean LDV exposure was 57% 	
			higher in patients with severe RI	
Jm L				
ß			(n=17) than in the LDV/SOF	
<u> </u>	10,000 -		Phase 2/3 population (N=1602)	
			 This result is consistent with 	
F			the PK difference observed	
ň			following administration of a	
A	1000 -		single LDV dose to subjects	
>			with severe RI or normal renal	
			function in a Phase 1 study	
_				
	100 Dhase	2/2* Source DI		
	Phase			
*Includes	100 Phase patients with normal renal function (CLcr ≥90			
*Includes	Phase			
	Phase patients with normal renal function (CLcr ≥90			
	Phase	0 mL/min).	LDV/SOF, 12 Weeks	
	Phase patients with normal renal function (CLcr ≥90	0 mL/min). Patients, n (%)	LDV/SOF, 12 Weeks n=18	
	Phase patients with normal renal function (CLcr ≥90	0 mL/min). Patients, n (%) Any AE	LDV/SOF, 12 Weeks	
	Phase patients with normal renal function (CLcr ≥90	0 mL/min). Patients, n (%) Any AE AE in >15% of patients	LDV/SOF, 12 Weeks n=18 13 (72)	
	Phase patients with normal renal function (CLcr ≥90	0 mL/min). Patients, n (%) Any AE AE in >15% of patients Fatigue	LDV/SOF, 12 Weeks n=18 13 (72) 4 (22)	
Sa	Phase patients with normal renal function (CLcr ≥90 fety Summary	0 mL/min). Patients, n (%) Any AE AE in >15% of patients	LDV/SOF, 12 Weeks n=18 13 (72)	
Sa	Phase patients with normal renal function (CLcr ≥90	0 mL/min). Patients, n (%) Any AE AE in >15% of patients Fatigue Headache	LDV/SOF, 12 Weeks n=18 13 (72) 4 (22) 4 (22)	
Sa	Phase patients with normal renal function (CLcr ≥90 fety Summary	Patients, n (%) Any AE AE in >15% of patients Fatigue Headache Hyperkalemia Grade 3-4 AE Serious AE*	LDV/SOF, 12 Weeks n=18 13 (72) 4 (22) 4 (22) 3 (17)	
Sa	Phase patients with normal renal function (CLcr ≥90 fety Summary	D mL/min). Patients, n (%) Any AE AE in >15% of patients Fatigue Headache Hyperkalemia Grade 3–4 AE	LDV/SOF, 12 Weeks n=18 13 (72) 4 (22) 4 (22) 3 (17) 5 (28)	

*Acute kidney injury and noncardiac chest pain (n=1); dehydration and hypotension (n=1); acute renal failure (n=1); hypotension and syncope (n=1); †Elevated creatinine (Grade 3, n=3); Grade 4, n=1); decreased hemoglobin (Grade 3, n=3; Grade 4, n=1); elevated glucose (Grade 3, n=3); decreased bicarbonate (Grade 3, n=1); decreased lymphocytes (Grade 3, n=3).

10 (56)

AEs were consistent with those expected for this population There was no clinically meaningful change in eGFR: there was a 1.2-mL/min/1.73m² decrease from baseline to end of treatment

There were no treatment-related cardiac AEs, including bradycardia There were no clinically meaningful changes in QTc intervals or other electrocardiographic parameters during treatment

 Comparison of echocardiograms obtained at baseline and Week 12 did not reveal any clinically significant changes; mean ejection fractions were 58% (range 53–70%) and 57% (49–63%), respectively

We extend our thanks to the patients and their families. This study was funded by Gilead Sciences. I

E. Lawitz: Gilead, AbbVie, Achillion, BMS, Boehringer Ingelheim, Enanta, GSK, Idenix, Intercept, Janssen, MSD, Nitto Denko, Novartis, Regulus, Salix, Theravance; C.S. Landis: Gilead, AbbVie, BMS, Conatus; B.J. Maliakkal: AbbVie, BMS, Grifols, Intercept, MSD, Valeant (Salix); M. Bonacini: Gilead, AbbVie, Allergan, Intercept, MSD, Pfizer, Proteus; G. Ortiz-Lasanta: nothing to disclose; J. Zhang, E. Mogalian, S. De-Oertel, A.O. Osinusi, D.M. Brainard, and J.G. McHutchison: Gilead; S.L. Flamm: Gilead, AbbVie, Intercept, Salix; S.C. Gordon: Gilead, AbbVie, Intercept, MSD; E.J. Gane: Gilead, AbbVie, Alios, Alnylam, Janssen, MSD.